Pseudouridine determination in blood serum as tumor marker.
A new method to measure pseudouridine (psi rd) in blood serum has been used to study patients with cancer of breast, lung, colon, and ovaries, and patients with hepatomas, non-Hodgkin lymphomas, and acute lymphoblastic leukemias, at different stages. The results indicate: (1) a significant (p less than 0.01) difference between the psi rd serum level of the cancer patient group and the normal control group; (2) that the increase of the level of serum psi rd is correlated both to the stage of the disease and to the spreading of the tumor tissue; (3) a correlation between the response to therapy and the behaviour of psi rd serum levels.
D001943:Breast Neoplasms / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D003110:Colonic Neoplasms / Q000097:blood; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood; D008223:Lymphoma / Q000097:blood; D009369:Neoplasms / Q000097:blood*; D010051:Ovarian Neoplasms / Q000097:blood; D011560:Pseudouridine / Q000097:blood*; D014529:Uridine / Q000031:analogs & derivatives*
D011560:Pseudouridine; D014529:Uridine